Receptor of Advanced Glycated End Products Gene Polymorphism in Patients with Rheumatoid Arthritis

Abstract

Background: Through its capacity to intensify inflammatory pathways, Rheumatoid arthritis (RA) has been connected to the receptor for  advanced glycation end products (RAGE). So, in those with rheumatoid arthritis, the RAGE gene polymorphism may be a significant  indicator of disease activity. Our aim is illustration of the role of RAGE gene polymorphism (G82S) in susceptibility of rheumatoid  arthritis.

Methods: Thirty individuals were used in this case control study, which was conducted at the Zagazig University hospitals'  Clinical Pathology, Rheumatology, and Rehabilitation departments after obtaining their written agreement for ethical reasons. The  participants were split up into two groups: fifteen RA cases and fifteen healthy volunteers who acted as the control group. A molecular  investigation of the RAGE gene's glycine-to-serine (G82S) polymorphism was done for genotyping.

Results: Rheumatoid arthritis patients  have allele G levels that are 7 times greater than those in the control group, with a 95% CI of 1.38 to 35.5. Significant difference:  p=0.009.

Conclusions: The RAGE gene polymorphism (G82S) with allele G was higher in rheumatoid arthritis patients than the control  group. Sadly, we were unable to discover a link between gene variation and disease activity.